Literature DB >> 23530101

Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

Lisa Martin1, Laura Birdsell, Neil Macdonald, Tony Reiman, M Thomas Clandinin, Linda J McCargar, Rachel Murphy, Sunita Ghosh, Michael B Sawyer, Vickie E Baracos.   

Abstract

PURPOSE: Emerging evidence suggests muscle depletion predicts survival of patients with cancer. PATIENTS AND METHODS: At a cancer center in Alberta, Canada, consecutive patients with cancer (lung or GI; N = 1,473) were assessed at presentation for weight loss history, lumbar skeletal muscle index, and mean muscle attenuation (Hounsfield units) by computed tomography (CT). Univariate and multivariate analyses were conducted. Concordance (c) statistics were used to test predictive accuracy of survival models.
RESULTS: Body mass index (BMI) distribution was 17% obese, 35% overweight, 36% normal weight, and 12% underweight. Patients in all BMI categories varied widely in weight loss, muscle index, and muscle attenuation. Thresholds defining associations between these three variables and survival were determined using optimal stratification. High weight loss, low muscle index, and low muscle attenuation were independently prognostic of survival. A survival model containing conventional covariates (cancer diagnosis, stage, age, performance status) gave a c statistic of 0.73 (95% CI, 0.67 to 0.79), whereas a model ignoring conventional variables and including only BMI, weight loss, muscle index, and muscle attenuation gave a c statistic of 0.92 (95% CI, 0.88 to 0.95; P < .001). Patients who possessed all three of these poor prognostic variables survived 8.4 months (95% CI, 6.5 to 10.3), regardless of whether they presented as obese, overweight, normal weight, or underweight, in contrast to patients who had none of these features, who survived 28.4 months (95% CI, 24.2 to 32.6; P < .001).
CONCLUSION: CT images reveal otherwise occult muscle depletion. Patients with cancer who are cachexic by the conventional criterion (involuntary weight loss) and by two additional criteria (muscle depletion and low muscle attenuation) share a poor prognosis, regardless of overall body weight.

Entities:  

Mesh:

Year:  2013        PMID: 23530101     DOI: 10.1200/JCO.2012.45.2722

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  663 in total

1.  Exploiting tumor metabolism: challenges for clinical translation.

Authors:  Matthew G Vander Heiden
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Quantifying the effect of slice thickness, intravenous contrast and tube current on muscle segmentation: Implications for body composition analysis.

Authors:  Georg Fuchs; Yves R Chretien; Julia Mario; Synho Do; Matthias Eikermann; Bob Liu; Kai Yang; Florian J Fintelmann
Journal:  Eur Radiol       Date:  2018-01-09       Impact factor: 5.315

3.  Fenofibrate prevents skeletal muscle loss in mice with lung cancer.

Authors:  Marcus D Goncalves; Seo-Kyoung Hwang; Chantal Pauli; Charles J Murphy; Zhe Cheng; Benjamin D Hopkins; David Wu; Ryan M Loughran; Brooke M Emerling; Guoan Zhang; Douglas T Fearon; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

4.  Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer.

Authors:  M D Goncalves; S Taylor; D F Halpenny; E Schwitzer; S Gandelman; J Jackson; A Lukose; A J Plodkowski; K S Tan; M Dunphy; L W Jones; R J Downey
Journal:  Clin Radiol       Date:  2018-01-06       Impact factor: 2.350

5.  A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.

Authors:  Elizabeth J Carey; Jennifer C Lai; Christopher Sonnenday; Elliot B Tapper; Puneeta Tandon; Andres Duarte-Rojo; Michael A Dunn; Cynthia Tsien; Eric R Kallwitz; Vicky Ng; Srinivasan Dasarathy; Matthew Kappus; Mustafa R Bashir; Aldo J Montano-Loza
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

6.  Skeletal Muscle Metrics on Clinical 18F-FDG PET/CT Predict Health Outcomes in Patients with Sarcoma.

Authors:  Brent Foster; Robert D Boutin; Leon Lenchik; David Gedeon; Yu Liu; Vinay Nittur; Ramsey D Badawi; Chin-Shang Li; Robert J Canter; Abhijit J Chaudhari
Journal:  J Nat Sci       Date:  2018

7.  Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Monzr M Al Malki; Nitya Nathwani; Dongyun Yang; Saro Armenian; Sanjeet Dadwal; Jaroslava Salman; Sally Mokhtari; Thai Cao; Karamjeet Sandhu; Michelle Rouse; Matthew Mei; Haris Ali; Pablo Parker; Joseph Alvarnas; Eileen Smith; Margaret O Donnell; Guido Marcucci; David Snyder; Auayporn Nademanee; Stephen J Forman; Anthony Stein; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-09       Impact factor: 5.742

Review 8.  Diagnostic imaging of osteoporosis and sarcopenia: a narrative review.

Authors:  Carmelo Messina; Gabriele Maffi; Jacopo Antonino Vitale; Fabio Massimo Ulivieri; Giuseppe Guglielmi; Luca Maria Sconfienza
Journal:  Quant Imaging Med Surg       Date:  2018-02

9.  Proteomic identification of potential markers of myosteatosis in human urine.

Authors:  Holger Husi; Alisdair MacDonald; Richard J E Skipworth; Janice Miller; Andrew Cronshaw; Kenneth C H Fearon; James A Ross
Journal:  Biomed Rep       Date:  2018-04-25

Review 10.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.